HOME >> BIOLOGY >> NEWS
Scientists identify novel gene driving the growth and survival of melanoma cells

BOSTON--A team of researchers led by scientists at Dana-Farber Cancer Institute have discovered a genetic abnormality in the cells of some advanced melanoma patients that worsens their chances of survival, but also might be a target of future drug attack against the dangerous skin cancer.

Dana-Farber's Levi Garraway, MD, PhD, and William Sellers, MD, the paper's first and senior authors, and their colleagues will report their findings in the July 7 issue of the journal Nature.

"By pinpointing the abnormally multiplied MITF oncogene, we may be able to develop better diagnostic and prognostic tools as well as provide a target for highly specific therapies for metastatic melanoma patients who have this overcopied gene," explains Sellers, who also holds an appointment with the Broad Institute of Harvard and MIT and with Harvard Medical School.

Melanoma accounts for just six percent of diagnosed skin cancer cases in the United States, but it is the deadliest, causing three quarters of all skin cancer related deaths. The American Cancer Society estimates that 7,700 melanoma patients will die this year.

Caused mainly by sun exposure, melanoma has been increasing rapidly over the past several decades. Nearly 60,000 new cases are expected in 2005. Most cases caught early can be cured, but if melanoma cells penetrate the skin deeply, the cancer is highly prone to spread with life-threatening consequences despite treatment with surgery, chemotherapy and radiation.

The researchers used single nucleotide polymorphism (SNP) array technology, which focuses on the building blocks of individual genes, to identify regions of chromosomes where genes were either left out or multiplied over and over mistakes that are often associated with cancer.

In studying cells from primary and metastatic melanoma tumors, the scientists observed as many as 13 extra copies of the MITF gene in 10 percent of primary melanomas and 21 percent of meta
'"/>

Contact: Bill Schaller
william_schaller@dfci.harvard.edu
617-632-5357
Dana-Farber Cancer Institute
6-Jul-2005


Page: 1 2 3

Related biology news :

1. Scientists show that mitochondrial DNA variants are linked to risk factors for type 2 diabetes
2. Scientists prove that disputed Korean stem cell line comes from an unfertilized egg and not cloning
3. Scientists move closer to bio-engineered bladders
4. Scientists find stem cell switch
5. Scientists discover new way to study nanostructures
6. Scientists a step closer to understanding how anaesthetics work in the brain
7. Scientists to make news at Computational Biology Conference
8. Accident-prone? Scientists link brain function to knee injuries
9. Scientists take next step in understanding potential target for ovarian cancer treatment
10. Scientists find brown fat master switch
11. Scientists identify 2 distinct Parkinsons networks

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/26/2020)... ... August 25, 2020 , ... ... company developing novel pharmaceuticals targeting mitochondria, in partnership with Essex Bio-Technology, a ... its pivotal U.S. Phase 3 VISTA-2 study of SkQ1 ophthalmic solution in ...
(Date:8/26/2020)... ... August 25, 2020 , ... Modality Solutions, a ... 2020 annual Inc. 5000 list. The list is the most prestigious ranking of the ... well, and for this year’s list, reported three-year revenue growth of 71 percent. ...
(Date:8/21/2020)... ... August 18, 2020 , ... Sentien Biotechnologies, ... that the U.S. Food and Drug Administration (FDA) has approved the company’s Investigational ... the treatment of severe COVID-19. Approval of this IND allows Sentien to initiate ...
Breaking Biology News(10 mins):
(Date:8/15/2020)... Ore. (PRWEB) , ... August 13, 2020 , ... ... the creation of its Scientific Advisory Board (SAB) to research the medical potential ... cannabis can be enhanced when combined with terpenes. The board is focused on expanding ...
(Date:8/12/2020)... ... August 12, 2020 , ... ... International), a global leader in FDA compliance consulting has been named on its ... companies. The list represents a unique look at the most successful companies within ...
(Date:7/31/2020)... ... July 29, 2020 , ... R3 Stem Cell International is now offering patients ... million stem cells total, patients may choose which extremities they would like treated. , ... (BMC Musculoskelet Disord. 2016). At R3 International, umbilical cord tissue is obtained from a ...
(Date:7/31/2020)... and SOMERSET, N.J (PRWEB) , ... July 29, ... ... genome editing company, and Catalent, the leading global provider of advanced delivery technologies, ... health products, today announced that they have entered into a strategic partnership whereby ...
Breaking Biology Technology:
Cached News: